Area of research
Otorhinolaryngology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Radiation therapy, Internal medicine, Oncology, Lung cancer, and Chemoradiotherapy.
Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care
Re-examining post-operative chemoradiotherapy in head and neck cancer: an updated long-term combined analysis of RTOG 9501/EORTC 22931
Adaptive vs. Non-Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC): Indirect Comparison of NRG-RTOG 0617 and 1106 Individual Patient Data
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539
Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).
Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect?
Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.
Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.
Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative
A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer
Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis
Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial
Higher Radiation Dose to Immune System is Correlated With Poorer Survival in Patients With Stage III Non–small Cell Lung Cancer: A Secondary Study of a Phase 3 Cooperative Group Trial (NRG Oncology RTOG 0617)
Pretreatment<sup>18</sup>F-FDG PET Textural Features in Locally Advanced Non–Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235
Optimal Treatment Selection of Stereotactic Body Radiation Therapy and Intensity Modulated Radiation Therapy for Reirradiation of Head and Neck Cancer: A Multi-Institution Comparison
Multi-Institution Analysis of Intensity Modulated Radiation Therapy–Based Reirradiation for Head and Neck Cancer: Prognostic Factors and Recursive Partitioning Analysis for Overall Survival
Reirradiation Outcomes After Upfront Larynx Preservation or Total Laryngectomy: A Multi-institutional Analysis
Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline
Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline
Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234
Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas
Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma
NCI–RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers